The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.

ABSTRACT:

Purpose

The proliferation of breast epithelial cells increases during the luteal phase of the menstrual cycle, when they are exposed to progesterone, suggesting that ulipristal acetate, a selective progestin-receptor modulator (SPRM), may reduce breast cell proliferation with potential use in breast cancer chemoprevention.

Methods

Women aged 18-39 were randomized 1:1 to ulipristal 10-mg daily or to a combination oral contraceptive (COC) for 84 days. Participants underwent a breast biopsy and breast MRI at baseline and at end of study treatment. Proliferation of breast TDLU cells was evaluated by Ki67 immunohistochemical stain. We evaluated the breast MRIs for background parenchymal enhancement (BPE). All slides and images were masked for outcome evaluation.

Results

Tw

SUBMITTER: Westhoff CL 

PROVIDER: S-EPMC10088437 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature